Neumora Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
NMRA$0.47-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(53,721) | $(35,625) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 7,373 | 2,195 |
| Non-cash operating lease expense | 791 | 799 |
| Depreciation and amortization | 158 | 158 |
| Net accretion of investments in marketable securities | (1,147) | (892) |
| Other noncash expenses | — | 15 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 7,351 | 7,858 |
| Accounts payable | 1,155 | (6,012) |
| Accrued liabilities | (4,113) | (736) |
| Operating lease liabilities | (802) | (801) |
| Net cash used in operating activities | (42,955) | (33,041) |
| Investing activities: | ||
| Purchases of marketable securities | (185,804) | (41,483) |
| Proceeds from sales and maturities of marketable securities | 36,578 | 44,336 |
| Purchases of property and equipment | — | (36) |
| Cash paid for acquisition of assets | (775) | — |
| Net cash (used in) provided by investing activities | (150,001) | 2,817 |
| Financing activities: | ||
| Proceeds from exercise of stock options | 1,845 | 602 |
| Repurchase of unvested early exercised shares | — | (491) |
| Payments for deferred offering costs | — | (10) |
| Net cash provided by financing activities | 1,845 | 101 |
| Net change in cash and cash equivalents and restricted cash | (191,111) | (30,123) |
| Cash and cash equivalents and restricted cash at beginning of year | 375,251 | 242,206 |
| Cash and cash equivalents and restricted cash at end of year | $184,140 | $212,083 |
| Components of cash and restricted cash: | ||
| Cash and cash equivalents | $182,927 | $210,870 |
| Restricted cash | 1,213 | 1,213 |
| Total cash and cash equivalents and restricted cash | $184,140 | $212,083 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.